Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Accounts Payables (2018 - 2025)

China SXT Pharmaceuticals (SXTC) has 8 years of Accounts Payables data on record, last reported at $7.3 million in Q1 2025.

  • For Q1 2025, Accounts Payables rose 468.01% year-over-year to $7.3 million; the TTM value through Mar 2025 reached $7.3 million, up 468.01%, while the annual FY2025 figure was $7.3 million, 468.01% up from the prior year.
  • Accounts Payables reached $7.3 million in Q1 2025 per SXTC's latest filing, up from $1.3 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $7.3 million in Q1 2025 and bottomed at $1.3 million in Q1 2024.
  • Average Accounts Payables over 5 years is $3.3 million, with a median of $3.0 million recorded in 2021.
  • Peak YoY movement for Accounts Payables: plummeted 60.96% in 2023, then soared 468.01% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $3.0 million in 2021, then rose by 15.84% to $3.5 million in 2022, then tumbled by 60.96% to $1.4 million in 2023, then fell by 7.14% to $1.3 million in 2024, then skyrocketed by 468.01% to $7.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $7.3 million in Q1 2025, $1.3 million in Q1 2024, and $1.4 million in Q1 2023.